Curonix Bets on Non-Integrated Neurostimulation, Appoints CFO for Growth Phase

Pompano Beach, FL – November 6, 2025 – Curonix LLC, a medical technology company developing innovative therapies for chronic pain, has appointed Russell Fleeger as Chief Financial Officer, effective immediately. The move signals a pivotal shift for the company as it prepares to scale its proprietary Freedom Peripheral Nerve Stimulation (PNS) System and address a growing market demanding non-opioid alternatives.

Fleeger brings over 25 years of global finance experience, including two decades within the medical device industry, most recently as CFO of a major segment at Franklin Electric Co., Inc. Prior to that, he spent 18 years at Biomet and Zimmer Biomet Holdings, Inc. – a pedigree that Curonix leadership believes will be instrumental in navigating the complexities of commercialization and future growth.

“Russell’s appointment is more than just filling a role; it’s a strategic investment in our future,” said a Curonix executive. “We’re at a critical inflection point, and his experience scaling medical device businesses will be invaluable.”

A Shift in Pain Management

The timing of Fleeger’s arrival is significant. The United States is grappling with a persistent opioid crisis, prompting a surge in demand for alternative pain management solutions. Traditional methods often come with debilitating side effects or limited efficacy, leaving millions searching for relief. Peripheral Nerve Stimulation (PNS) has emerged as a promising alternative, but existing technologies often involve surgically implanted batteries that require replacement and carry associated risks.

Curonix aims to disrupt this landscape with its Freedom PNS System. Unlike conventional PNS devices, the Freedom System is non-integrated and battery-free. It utilizes High-Frequency Electromagnetic Coupling (HF-EMC) to wirelessly power the implanted neurostimulator, eliminating the need for battery replacements and potentially reducing surgical complexity and complications. The system’s two-component design – an electrode array and a separate receiver – allows for implantation in separate incisions, further minimizing invasiveness.

“The appeal of a non-integrated, wireless system is significant, both for physicians and patients,” explains an independent medical device analyst. “Reducing surgical complexity and the risk of battery-related complications could lead to wider adoption of PNS therapy.”

Beyond Technology: The Business of Scaling

While the technology is compelling, bringing a novel medical device to market requires substantial financial and operational expertise. Curonix has already secured $25 million in Series B funding led by HealthLink Capital, following a $10 million Series A round in 2022. These funds are earmarked for commercialization and expansion of the sales team.

“Scaling a medical device company requires a unique skillset,” says Fleeger. “It’s not just about revenue growth; it’s about building a sustainable business model, navigating regulatory hurdles, and managing complex supply chains.”

Fleeger’s experience at Zimmer Biomet, a global leader in orthopedic implants, is particularly relevant. During his tenure, he oversaw significant growth and operational improvements, including international expansion and the integration of acquired businesses. This experience will be crucial as Curonix seeks to expand its market reach beyond the United States.

“One of the biggest challenges for early-stage medical device companies is navigating the reimbursement landscape,” adds the medical device analyst. “Fleeger’s experience in securing reimbursement coverage for innovative technologies will be a key asset.”

Competitive Landscape and Future Outlook

The PNS market is becoming increasingly crowded, with established players like Nevro Corp and Boston Scientific vying for market share. Nevro, the current market leader, boasts a robust HF10 therapy platform and a well-established sales network. Boston Scientific offers the Spectra WaveWriter System, leveraging its extensive distribution capabilities. Stimwave is another key competitor, focusing on non-invasive PNS solutions.

Curonix differentiates itself through its non-integrated, battery-free design and targeted approach to chronic pain indications. The company is initially focusing on conditions underserved by existing PNS therapies, such as complex regional pain syndrome (CRPS) and peripheral neuropathy.

“We believe there’s a significant unmet need for innovative pain management solutions,” says a Curonix spokesperson. “Our Freedom PNS System offers a unique combination of efficacy, safety, and patient comfort.”

Analysts predict that the PNS market will continue to grow in the coming years, driven by the increasing prevalence of chronic pain and the demand for non-opioid alternatives. Curonix, with its innovative technology and experienced leadership, is well-positioned to capture a significant share of this expanding market. However, success will depend on its ability to effectively navigate the competitive landscape, secure regulatory approvals, and demonstrate the clinical and economic value of its Freedom PNS System.

The appointment of Russell Fleeger as CFO is a clear signal that Curonix is committed to building a sustainable, scalable business and delivering meaningful value to patients suffering from chronic pain. The coming years will be critical as the company strives to transform the pain management landscape and establish itself as a leader in the field of neurostimulation.